ZNTL - Zentalis Pharmaceuticals Llc

ZNTL - Zentalis Pharmaceuticals Llc

https://zentalis.com

Recent News

Powered by Alpha Vantage

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Zentalis Pharma ( NASDAQ:ZNTL )

Benzinga • 1 week, 5 days ago • score: 0.08

SAN DIEGO, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc.

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire • 2 weeks, 3 days ago • score: -0.06

SAN DIEGO, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that ...

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 2 months, 1 week ago • score: 0.17

SAN DIEGO, July 01, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on ...

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 3 months, 1 week ago • score: 0.16

SAN DIEGO, June 02, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on ...

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Zentalis Pharma ( NASDAQ:ZNTL )

Benzinga • 4 months, 1 week ago • score: 0.07

SAN DIEGO, May 01, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc.

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

GlobeNewswire • 4 months, 1 week ago • score: 0.17

SAN DIEGO, May 01, 2025 ( GLOBE NEWSWIRE ) -- Zentalis® Pharmaceuticals, Inc. ( Nasdaq: ZNTL ) , a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on May ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.

52W High

$5.44

52W Low

$1.01

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.77

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.31

EV/Revenue (<3 favorable)

7.77

P/S (TTM) (<3 favorable)

4.70

P/B (<3 favorable)

0.46

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

13.54%

Institutions (25–75% balanced)

76.32%

Shares Outstanding

72,136,000

Float

49,978,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

26,865,000

Gross Profit (TTM)

26,865,000

EPS (TTM)

-2.28

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-6.38%

ROE (TTM) (>15% strong)

-0.50%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—